Business & Finance

Home | Pharma Manufacturing

pharmamanufacturing.com

Pharma Manufacturing provides news, analysis and examples of how leading pharmaceutical companies are tackling drug development, scale-up and manufacturing challenges.

Articles48

FDA’s proposed plausible mechanism framework presents CMC challenges

Novartis plans new active pharmaceutical ingredients facility in North Carolina

CMC for cell and gene therapies remains a ‘learning curve’ for Big Pharma

PCI Pharma Services makes $1B investment to scale injectable manufacturing, device assembly

WuXi Biologics on track for 2026 GMP release at microbial manufacturing site in China

China poised to eclipse US innovators with surge in global licensing

AbbVie to build new $1.4B manufacturing campus in North Carolina

Eli Lilly scales global manufacturing with learn once, deploy everywhere approach

Neion Bio emerges with egg-based biologics platform, biosimilar deal

Axplora leverages ADC investments, bolsters offerings to target fast-growing modality

Trump’s FY27 budget proposes $325M increase for domestic pharma manufacturing

Fujifilm doubles quality control footprint at Danish commercial-scale manufacturing site

AGC Biologics to expand CDMO capabilities in Japan with new $350M Yokohama site

US drug supply at risk from single-country KSM sources: report

Eli Lilly continues to invest in China to strengthen local production of GLP-1 drugs

Q1 leading indicator data provides positive outlook for biopharma outsourcing

Contract manufacturing deals for drugs marketed in US shift to Europe: GlobalData

US-Iran ceasefire provides potential relief for pharma logistics, cost structures

Lonza’s specialized modalities business lags the CDMO’s other two units

Trump tariff order pushes onshore drug manufacturing longer term: analysts

Trump signs order imposing 100% tariff on patented pharmaceuticals, ingredients

Siegfried’s addition of drug substance capacity is part of long-term growth strategy

Novartis expands radioligand therapy manufacturing, offers scalable blueprint

Thermo Fisher continues to invest in pharma services capabilities in 2026

Lotte Biologics sees ADC manufacturing capabilities in New York as key differentiator

Celltrion pledges $800M to expand manufacturing capacity at South Korea headquarters

Fujifilm’s $8B manufacturing investment positions CDMO as end-to-end partner

UCB plans to build $2B biologics manufacturing facility in Georgia

WuXi AppTec reports record revenue in 2025 despite US-China geopolitical tensions

API Innovation Center works to reshore generic drug production

AstraZeneca plans commercial cell therapy manufacturing, R&D hub in Shanghai

Congress looks to address US dependence on China for APIs, KSMs

Fujifilm replicates Denmark facility in North Carolina using modular approach

Lifecore expects 2026 revenue to decline by 12%-15% due to customer-driven factors

FDA hits Simtra BioPharma Solutions with warning letter over German site

11 potential blockbuster drugs to watch in 2026

ElevateBio’s BaseCamp Pittsburgh seen as model for growing US biomanufacturing

Novo Nordisk gets Form 483 from FDA after inspection at Plainsboro, NJ site

FDA regulatory actions regarding Novo Nordisk site result in CRL for Incyte

Lonza divests capsules and health ingredients business for $2.2B in upfront cash

Drugmakers and CDMOs seize GLP-1 opportunity, invest in manufacturing facilities

Stevanato Group’s GLP-1 revenue grows more than 50% in 2025

Eli Lilly feels strain of its $50B US capital expansion since 2020

A mix of old and new, Basel emerges as a leading European biopharma hub

Novo Nordisk expands Irish facility with $500M investment to manufacture oral GLP-1s

WuXi Biologics accelerates development, manufacturing with robust model, platforms

Agilent’s Biovectra drives GLP-1 growth with ‘healthy’ contribution from the CDMO

Charles River inks agreement to divest CDMO, cell solutions businesses to GI Partners